Amylyx Pharmaceuticals

The work to support the global #neurodegenerative disease community never stops. Subscribe for the latest updates from Amylyx at www.amylyx.com.

#DYK that there are no approved therapies for post-bariatric hypoglycemia (PBH), a potentially life-threatening complication of bariatric surgery? PBH is thought to be caused by exaggerated secretion of glucagon-like peptide-1 (GLP-1) leading to hypersecretion of insulin and a rapid drop in blood sugar. Symptoms can result in major disruptions to daily living, including falls, motor vehicle accidents, and job and income loss.

Today, we announced the publication of exploratory analyses on cerebrospinal fluid biomarkers from participants with Alzheimer’s disease from the Phase 2 PEGASUS trial. These findings suggest that our investigational therapy engages multiple pathological pathways related to neurodegeneration, including tau. Results were published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions, a journal of the @Alzheimer’s Association. Learn more: https://bit.ly/3YExBVa

Today, we announced that the European Commission has granted Orphan Drug Designation for our investigational treatment for Wolfram syndrome. We look forward to reporting topline data this fall from the Phase 2 HELIOS trial, with the ultimate aim of addressing an urgent unmet medical need for this community. Read more: https://bit.ly/3LUmKi8

ALS impacts communities of all different backgrounds. Today, we’re spotlighting I AM ALS’ Outreach and Inclusion Initiative, which seeks to expand access to critical #ALS support, resources and services, including mental health, to under-resourced communities. #MinorityMentalHealthAwarenessMonth    Learn more:  https://lnkd.in/dyv3ttzY 

Recently, our co-CEOs Josh and Justin participated in The ALS Association's annual CEO Soak in Boston. As a community, it’s critical that we continue to research with urgency as part of our collective mission to one day make ALS a chronic, manageable condition until we find a cure.     We’re proud to continue supporting important advocacy and awareness-building efforts as part of this mission.  

Today, we announced the acquisition of an investigational, Phase 3-ready GLP-1 receptor antagonist for the potential treatment of hyperinsulinemic hypoglycemia. We look forward to studying this new scientific pathway, building on our endocrine and neuroscience expertise, and advancing our mission to bring new therapies forward for communities with unmet needs. Read more: https://lnkd.in/dR2C2jef

Amylyx’ Evan Mizerak is presenting data from our preclinical program in #ALS at the Oligonucleotides for CNS Summit in Boston this week. More details below.

Our work is far from over, and we will not stop discovering, developing, and advocating on behalf of the ALS community who urgently need new treatment options. Every day reinforces our commitment to discover and develop more treatment options for those suffering from ALS and other #neurodegenerative diseases.

#DYK common symptoms of #Wolframsyndrome include juvenile diabetes mellitus, optic atrophy, and deafness. Learn more about the causes and symptoms that affect those living with Wolfram.